Project Details
Projekt
CP2 Biomedical Informatics Support Platform (BISP)
Subject Area
Gastroenterology
Medical Informatics and Medical Bioinformatics
Medical Informatics and Medical Bioinformatics
Term
since 2020
Project identifier
Deutsche Forschungsgemeinschaft (DFG) - Project number 426671079
The Biomedical Informatics Support Platform (BISP) of CP2 supports the CRU5002 translational research endeavors through 3 key components: 1. It aims to develop infrastructure to facilitate the data management of both clinical and research data. 2. It implements cutting-edge sequencing methods and advanced analytical techniques. 3. It offers a wide range of bioinformatics pipelines and expert guidance to enable data analysis and effective data integration. During the first funding period, CP2 has achieved remarkable results in all three areas: 1. A SEEK-based system, instrumental in managing and providing accessible data to all CRU5002 members, as well as a local cBioPortal platform that facilitates efficient integration of experimental and clinical data. 2. Establishment of innovative single- cell omics methods, specifically designed and optimized for pancreatic cancer (PDAC) samples has overcome technical limitations, expanding current and enabling new possibilities for PDAC studies. 3. Integration of state-of-the-art bioinformatic techniques, with a particular focus on PDAC subtyping, genome dynamics and gene regulatory networks that has substantially strengthened the capabilities of the CRU5002, addressing critical challenges and presenting exciting opportunities for future advancements. Our focus lies in comprehensively characterizing genomic concordances and differences between primary PDAC, PDO, PDX and CDX models. This emphasis will persist throughout the second funding period and will be extended to the integration of functional data from translational PDAC models. CP2 will continuously maintain and refine the centralized platforms and NGS methods, set up new methods and standards for data generation and integrative data analysis including consulting and training for these platforms and methods. We will develop and employ further new sequencing strategies in single cell- omics. We will develop additional data analysis pipelines and methods for gene regulatory networks, and for analyzing genome dynamics. In order to pursue translation of CRU5002 findings into clinical practice, another focus will be on the integration of experimental and clinical data. Hence, CP2 does not only catalyze collaborations with and among the SPs and CP1, but is instrumental for the successful overall aim of the CRU5002 to implement stratification-based PDAC therapy based on genome dynamics.
DFG Programme
Clinical Research Units
